BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Hovione´s Rapid Proof of Concept Dry Powder Inhalation Product Development


10/19/2011 12:01:50 PM

LOURES, Portugal, October 19, 2011 /PRNewswire/ --

Hovione today announced the launch of its Rapid Proof of Concept Study for the development of dry powder inhalation (DPI) products.

Building on Hovione´s well established DPI development capability, the new service simplifies the development of formulations, producing a proof of concept formulation of a client´s molecule in just a few weeks.

Hovione has simplified DPI product development, reduced complexity and reduced the time required for completion by mastering, in concert, particle engineering, formulation technology and inhaler design, the three disciplines vital to the development of a successful product. Unlike other CROs, Hovione has all of this expertise under one roof, eliminating the coordination issues clients often experience in having to use multiple CROs. The results of this are reduced coordination costs, shortened development timescales and a stream-lining of the development process.

Peter Villax, Hovione´s Vice President of Pharma & Innovation commented "this new Rapid Proof of Concept service offers clients a low risk look at the feasibility of developing a DPI product and gives clients greater confidence about going into later stage development." He added, "Clients of the new service don´t just get a report, they get their first DPI formulation."

In a short period of time and for relatively little investment, a drug developer can acquire a DPI formulation, potentially adding significant value to an early stage out-licensing opportunity or helping a company move into a stronger position in funding negotiations with venture capitalists.

About Hovione. Hovione is an international company with over 50 years' experience in Active Pharmaceutical Ingredient development and compliant manufacture. With four FDA inspected sites in the U.S., China, Ireland, and Portugal, the company focuses on the most demanding customers, in the most regulated markets. The company also offers integrated API, particle design and formulation development and manufacturing. In the inhalation area, Hovione is the only independent company offering such a broad range of services.


Contacts at Hovione:
Phil Nelson, PhD
Business Development Manager
pnelson@hovione.com
+351-219-847-619

Isabel Pina
Marketing & Communication
ipina@hovione.com
+351-21-982-9362

http://www.hovione.com


SOURCE Hovione



Read at BioSpace.com

Hovione
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES